Mexican clinical practice guidelines of immunotherapy 2011;Guía Mexicana de práctica clínica de inmunoterapia 2011

Revista Alergia Mexico

Volumn 58, Issue 1, 2011, Pages 3-51

  Larenas Linnemann, Désirée ^a   Ortega Martell, José Antonio ^b   Del Río Navarro, Blanca ^c   Rodríguez Pérez, Noel ^d   Arias Cruz, Alfredo ^e   Estrada, Alan ^f   Becerril Ángeles, Martín ^g   Pietropaolo Cienfuegos, Dino R ^c   De Jesús Ambriz Moreno, Maria ^d   Báez Loyola, Carlos ^a   Cossío Ochoa, Enna ^a   González Díaz, Sandra Nora ^e   Hidalgo Castro, Emilia María ^c   Huerta Hernández, Rosa Elena ^b   Macías Weinmann, Alejandra ^e   Oyoqui Flores, Joel ^f   Stone Aguilar, Héctor ^h   Treviño Salinas, Marisol Belinda ^e   Del Carmen Zárate Hernández, María ^e  

^a LIVER RESEARCH UNIT   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE HIDALGO   (Mexico)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^f IMSS ^*

^g INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^h UNIVERSIDAD DEL VALLE DE MÉXICO   (Mexico)

Author keywords

Adrenaline; Allergen immunotherapy; Allergy diagnosis; Anaphylaxis; Asthma; Atopic dermatitis; House dust mite; Mexico; Pollens; Rhinitis; Skin testing; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGY; CONSENSUS DEVELOPMENT; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; MEDICAL LITERATURE; MEDICAL SPECIALIST; MEXICO; MORBIDITY; PATIENT SAFETY; PRACTICE GUIDELINE; RESIDENT; REVIEW; SKIN TEST; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; ANIMAL; ASTHMA; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; PYROGLYPHIDAE;

ALLERGEN;

ALLERGENS; ANIMALS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; PYROGLYPHIDAE; SKIN TESTS; SUBLINGUAL IMMUNOTHERAPY;

EID: 84858038025     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (277)

1. Sole D, Mallol J, Camelo-Nunes IC, Wandalsen GF. Prevalence of rhinitis-related symptoms in Latin American children - Results of the International Study of Asthma and Allergies in Childhood (ISAAC) phase three. Pediatr Allergy Immunol 2010;21(1 Pt 2):e127-36.
2. Barraza-Villarreal A, Hernandez-Cadena L, Moreno-Macias H, et al. Trends in the prevalence of asthma and other allergic diseases in schoolchildren from Cuernavaca, Mexico. Allergy Asthma Proc 2007;28:368-74.
3. Ait-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009;64:123-48.
4. Lai CK, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009;64:476-83.
5. Rico-Mendez FG, Barquera S, Cabrera DA, et al. Bronchial asthma healthcare costs in Mexico: analysis of trends from 1991-1996 with information from the Mexican Institute of Social Security. J Investig Allergol Clin Immunol 2000;10:334-41. (Pubitemid 32113027)
6. Lopez Perez G, Morfin Maciel BM, Huerta Lopez J, et al. [Prevalence of allergic diseases in Mexico City]. Rev Alerg Mex 2009;56:72-9.
7. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102(4 Pt 1):558-62.
8. Pedroza A, Becerril M. [Consenso nacional de inmunoterapia]. Rev Alerg Mex 1998;45(Supl may).
9. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
10. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011;127(Suppl1):S1-S55.
11. Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009;64:669-77.
12. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. (Pubitemid 351632017)
13. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008;337:a744.
14. Bousquet PJ, Calderon MA, Demoly P, et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol. 2011;127:49-56.
15. Brozek JL, Baena-Cagnani CE, Bonini S, et al. Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008;63:38-46. (Pubitemid 350198245)
16. Becerril A, Canseco R, Barrera C, Angeles G. [Guía de Práctica Clínica, Diagnóstico y Tratamiento del Asma en Mayores de 18 Años]. Rev Inst Mex Seguro Social. 2009.
17. GRADE working group. GRADE assign quality of evidence. http://homepage3. nifty.com/aihara/sakusaku/GRADE-eng.html. 2009.
18. Oppenheimer J, Nelson HS. Skin testing. Ann Allergy Asthma Immunol 2006;96(Suppl 1):S6-S12. (Pubitemid 43287651)
19. Nelson HS, Oppenheimer J, Buchmeier A, et al. An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass. J Allergy Clin Immunol 1996;97:1193-201. (Pubitemid 26192266)
20. Krouse JH, Sadrazodi K, Kerswill K. Sensitivity and specificity of prick and intradermal testing in predicting response to nasal provocation with timothy grass antigen. Otolaryngol Head Neck Surg 2004;131:215-9. (Pubitemid 39208698)
21. Gungor A, Houser SM, Aquino BF, et al. A comparison of skin endpoint titration and skin-prick testing in the diagnosis of allergic rhinitis. Ear Nose Throat J 2004;83:54-60. (Pubitemid 38129613)
22. Río Navarro B, Mercado Ortiz V, Lerma Ortiz L, et al. [Comparación de 2 métodos de pruebas cutáneas para el diagnóstico de enfermedades alérgicas]. Rev Alerg Mex 1996;43:100-3.
23. Hamilton RG. Diagnosis and treatment of allergy to hymenoptera venoms. Curr Opin Allergy Clin Immunol 2010;10:323-9.
24. Bilo BM, Rueff F, Mosbech H, et al. Diagnosis of Hymenoptera venom allergy. Allergy 2005;60:1339-49. (Pubitemid 41476175)
25. Nepper-Christensen S, Backer V, DuBuske LM, Nolte H. In vitro diagnostic evaluation of patients with inhalant allergies: summary of probability outcomes comparing results of CLA- and CAP-specific immunoglobulin E test systems. Allergy Asthma Proc 2003;24:253-8. (Pubitemid 37152330)
26. Calabria CW, Dietrich J, Hagan L. Comparison of serum-specific IgE (ImmunoCAP) and skin-prick test results for 53 inhalant allergens in patients with chronic rhinitis. Allergy Asthma Proc 2009;30:386-96.
27. Hamilton RG. Clinical laboratory assessment of immediate-type hypersensitivity. J Allergy Clin Immunol 2010;125(Supp 2):S284-S296.
28. Khan DA. Allergic rhinitis with negative skin tests: does it exist? Allergy Asthma Proc 2009;30:465-9.
29. Larenas-Linnemann DL, Cruz AA, Fogelbach GA, del Prado ML. [Allergens used in skin tests in Mexico]. Rev Alerg Mex 2009;56:41-7.
30. Larenas-Linnemann DE, Fogelbach GA, Alatorre AM, et al. Patterns of skin prick test positivity in allergic patients: usefulness of a nationwide SPT chart review. Allergol Immunopathol (Madr) 2011 Jan 6.
31. Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008;100(Suppl 3):S1-S148. (Pubitemid 351409337)
32. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-24.
33. Bousquet PJ, Hooper R, Kogevinas M, et al. Number of allergens to be tested to assess allergenic sensitization in epidemiologic studies: results of the European Community Respiratory Health Survey I. Clin Exp Allergy 2007;37:780-7. (Pubitemid 46643066)
34. Long WF, Taylor RJ, Wagner CJ, et al. Skin test suppression by antihistamines and the development of subsensitivity. J Allergy Clin Immunol 1985;76:113-7. (Pubitemid 15230558)
35. Cook TJ, MacQueen DM, Wittig HJ, et al. Degree and duration of skin test suppression and side effects with antihistamines. A double blind controlled study with five antihistamines. J Allergy Clin Immunol 1973;51:71-7.
36. Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999;36:329-52. (Pubitemid 29261510)
37. Rao KS, Menon PK, Hilman BC, Sebastian CS, Bairnsfather L. Duration of the suppressive effect of tricyclic antidepressants on histamine-induced wheal-and-flare reactions in human skin. J Allergy Clin Immunol 1988;82(Pt 1):752-7. (Pubitemid 19003094)
38. Miller J, Nelson HS. Suppression of immediate skin tests by ranitidine. J Allergy Clin Immunol 1989;84(Pt 1):895-9. (Pubitemid 20022959)
39. Simons FE, Johnston L, Gu X, Simons KJ. Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast. Ann Allergy Asthma Immunol 2001;86:44-50. (Pubitemid 32104569)
40. Saarinen JV, Harvima RJ, Horsmanheimo M, Harvima IT. Modulation of the immediate allergic wheal reaction in the skin by drugs inhibiting the effects of leukotriene C4 and prostaglandin D2. Eur J Clin Pharmacol 2001;57:1-4. (Pubitemid 32391404)
41. Des Roches A, Paradis L, Bougeard YH, et al. Long-term oral corticosteroid therapy does not alter the results of immediate-type allergy skin prick tests. J Allergy Clin Immunol 1996;98:522-7. (Pubitemid 26377917)
42. Narasimha SK, Srinivas CR, Mathew AC. Effect of topical corticosteroid application frequency on histamine-induced wheals. Int J Dermatol 2005;44:425-7. (Pubitemid 40691991)
43. Sicherer SH, Eggleston PA. EMLA cream for pain reduction in diagnostic allergy skin testing: effects on wheal and flare responses. Ann Allergy Asthma Immunol 1997;78:64-8. (Pubitemid 27058325)
44. Danarti R, Waskito F, Indrastuti N. Onset and duration of action of topical antihistamine: a study of histamine skin test response. Int J Dermatol 2008;47:861-3.
45. Jones JD, Temino VM, Dworski R, et al. Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. Allergy Asthma Proc 2008;29:636-9.
46. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004;113:1129-36. (Pubitemid 38857996)
47. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006;117:169-75. (Pubitemid 43017156)
48. Oppenheimer J, Nelson HS. Skin testing: a survey of allergists. Ann Allergy Asthma Immunol 2006;96:19-23. (Pubitemid 43152662)
49. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1-S55.
50. Carr WW, Martin B, Howard RS, et al. Comparison of test devices for skin prick testing. J Allergy Clin Immunol 2005;116:341-6. (Pubitemid 41096541)
51. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25. (Pubitemid 43190146)
52. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9.
53. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008;121:512-8 e2.
54. Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol 2010;125:660-6.
55. Pastorello EA, Incorvaia C, Ortolani C, et al. Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. J Allergy Clin Immunol 1995;96(5 Pt 1):580-7.
56. Zarei M, Remer CF, Kaplan MS, et al. Optimal skin prick wheal size for diagnosis of cat allergy. Ann Allergy Asthma Immunol 2004;92:604-10. (Pubitemid 39243149)
57. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-3.
58. Position paper: Immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993;48(14 Suppl):7-35.
59. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147-334.
60. Powell RJ, Frew AJ, Corrigan CJ, Durham SR. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 2007;62:1335-8. (Pubitemid 47537501)
61. Canonica GW. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. WAO Journal 2010 19jun2010 [cited 2010 19 june]; Available from: http://www.allergychoices.com/school1000162/genie59/images/files/sub- lingual-immunotherapy-world-allergy.11.pdf
62. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008;38:19-42. (Pubitemid 350233401)
63. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;(4):CD001186.
64. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010;8:CD001186.
65. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;(1):CD001936.
66. Calderon MA. Meta-analyses of specific immunotherapy trials. Drugs Today (Barc) 2008;44(Suppl B):31-4.
67. Nieto A, Mazon A, Pamies R, et al. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J Allergy Clin Immunol 2009;124:157-61 e1-32.
68. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160.
69. Lewith GT, Watkins AD, Hyland ME, et al. Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial. BMJ 2002;324:520.
70. Radcliffe MJ, Lewith GT, Turner RG, et al. Enzyme potentiated desensitisation in treatment of seasonal allergic rhinitis: double blind randomised controlled study. BMJ 2003;327:251-4. (Pubitemid 36951593)
71. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-22. (Pubitemid 23110716)
72. Mirone C, Albert F, Tosi A, et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Clin Exp Allergy 2004;34:1408-14. (Pubitemid 39233696)
73. Nanda A, O'Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004;114:1339-44. (Pubitemid 39575887)
74. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:1356-65.
75. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005;60:801-7. (Pubitemid 40769884)
76. Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430-3. (Pubitemid 26266386)
77. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-75. (Pubitemid 29372886)
78. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow- up on the PAT study. Allergy 2007;62:943-8. (Pubitemid 47037870)
79. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608-13. (Pubitemid 41267135)
80. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951-60.
81. Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006;5:617-29. (Pubitemid 46021044)
82. Rosewich M, Schulze J, Fischer von Weikersthal-Drachenberg KJ, Zielen S. Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study. Pediatr Allergy Immunol 2010;21(1 Pt 2):e185-9.
83. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-55. (Pubitemid 44511559)
84. Senti G, Johansen P, Haug S, Bull C, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39:562-70.
85. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908-12.
86. Ewbank PA, Murray J, Sanders K, et al. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003;111:155-61. (Pubitemid 36143307)
87. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double- blind, placebo-controlled study. Allergy 2002;57:297-305. (Pubitemid 34280656)
88. Pifferi M, Baldini G, Marrazzini G, et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy 2002;57:785-90. (Pubitemid 34970000)
89. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-3. (Pubitemid 27173080)
90. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006;61:843-8. (Pubitemid 43893985)
91. Finegold I. Issues in stinging insect allergy immunotherapy: a review. Curr Opin Allergy Clin Immunol 2008;8:343-7.
92. Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy 2003;33:58-64. (Pubitemid 36114908)
93. Quercia O, Emiliani F, Pecora S, et al. Efficacy, safety, and modulation of immunologic markers by immunotherapy with honeybee venom: comparison of standardized quality depot versus aqueous extract. Allergy Asthma Proc 2006;27:151-8. (Pubitemid 43700868)
94. Steiss JO, Jodicke B, Lindemann H. A modified ultrarush insect venom immunotherapy protocol for children. Allergy Asthma Proc 2006;27:148-50. (Pubitemid 43700867)
95. Valentine MD, Schuberth KC, Kagey-Sobotka A, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990 6;323:1601-3.
96. Oude Elberink JN, de Monchy JG, Golden DB, et al. Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J Allergy Clin Immunol 2002;109:162-70. (Pubitemid 34112147)
97. Oude Elberink JN, De Monchy JG, Van Der Heide S, et al. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174-82. (Pubitemid 36132745)
98. Oude Elberink JN, van der Heide S, Guyatt GH, Dubois AE. Immunotherapy improves health-related quality of life of adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy 2009;39:883-9.
99. Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:370-4. (Pubitemid 11105963)
100. Goldberg A, Confino-Cohen R. Effectiveness of maintenance bee venom immunotherapy administered at 6-month intervals. Ann Allergy Asthma Immunol 2007;99:352-7. (Pubitemid 47606138)
101. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027-32. (Pubitemid 33151558)
102. Golden DB, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 2009;123:1371-5.
103. Golden DB, Kagey-Sobotka A, Norman PS, et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004;351:668-74.
104. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61:202-5. (Pubitemid 43381831)
105. Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007;37:1277-85. (Pubitemid 47372291)
106. Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99(6 Pt 1):744-51. (Pubitemid 27280363)
107. Bolhaar ST, Tiemessen MM, Zuidmeer L, et al. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double- blind food challenges. Clin Exp Allergy 2004;34:761-9. (Pubitemid 38736792)
108. Bucher X, Pichler WJ, Dahinden CA, Helbling A. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004;59:1272-6. (Pubitemid 39506725)
109. Asero R. Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 1998;28:1368-73. (Pubitemid 28559011)
110. Asero R. How long does the effect of birch pollen injection SIT on apple allergy last? Allergy 2003;58:435-8. (Pubitemid 36605733)
111. Boguniewicz M. The autoimmune nature of chronic urticaria. Allergy Asthma Proc 2008;29:433-8.
112. Practice parameters for allergen immunotherapy. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1996;98(6 Pt 1):1001-11.
113. Leynadier F, Banoun L, Dollois B, et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2001;31:988-96. (Pubitemid 32862827)
114. Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001;107:87-93. (Pubitemid 32105250)
115. Winther L, Malling HJ, Moseholm L, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. Allergy 2000;55:818-26. (Pubitemid 30643906)
116. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006;61:855-9. (Pubitemid 43893987)
117. Polosa R, Li Gotti F, Mangano G, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 2004;59:1224-8. (Pubitemid 39389479)
118. Webber CM, Calabria CW. Assessing the safety of subcutaneous immunotherapy dose adjustments. Ann Allergy Asthma Immunol 2010;105:369-75.
119. Muller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005;115:606-10. (Pubitemid 40341717)
120. Kivity S, Yarchovsky J. Relapsing anaphylaxis to bee sting in a patient treated with beta-blocker and Ca blocker. J Allergy Clin Immunol 1990;85:669-70. (Pubitemid 20099015)
121. White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008;101:426-30.
122. Stumpf JL, Shehab N, Patel AC. Safety of Angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacother 2006;40:699-703.
123. Consejo de Salubridad General. Manual de la comunicación e información. Manual de auditores: estándares para la certificación de hospitales 2009;pp:80-110.
124. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000;23:323-32.
125. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569-74, 74 e1-74 e7.
126. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-91. (Pubitemid 46527840)
127. Larenas-Linnemann D. Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing, and efficacy. Curr Allergy Asthma Rep 2008;8:465-74.
128. Lent AM, Harbeck R, Strand M, et al. Immunologic response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 2006;118:1249-56. (Pubitemid 44854124)
129. Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997;52:853-9. (Pubitemid 27359826)
130. Larenas Linnemann D, Guidos Fogelbach GA, Arias Cruz A. [Practice patterns in Mexican allergologists about specific immunotherapy with allergens]. Rev Alerg Mex 2008;55:53-61.
131. Larenas-Linnemann D, Cox LS. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol 2008;100:137-45. (Pubitemid 351238549)
132. Nelson HS. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol 2000;106(1 Pt 1):41-5. (Pubitemid 30482850)
133. Larenas-Linnemann D, Matta JJ, Shah-Hosseini K, et al. Skin prick test evaluation of Dermatophagoides pteronyssinus diagnostic extracts from Europe, Mexico, and the United States. Ann Allergy Asthma Immunol 2010;104:420-5.
134. Amar SM, Harbeck RJ, Sills M, et al Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009;124:150-6 e1-5.
135. Weber RW. Guidelines for using pollen cross-reactivity in formulating allergen immunotherapy. J Allergy Clin Immunol 2008;122:219-21. (Pubitemid 351899084)
136. Grier TJ, LeFevre DM, Duncan EA, Esch RE. Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts. Ann Allergy Asthma Immunol 2007;99:151-60. (Pubitemid 47264776)
137. Plunkett G. Stability of allergen extracts used in skin testing and immunotherapy. Curr Opin Otolaryngol Head Neck Surg 2008;16:285-91. (Pubitemid 351677667)
138. Zuberbier T, Bachert C, Bousquet PJ, et al. GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010;65:1525-30.
139. Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008;121:1120-5 e2.
140. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2003 Jan;90(1 Suppl 1):1-40.
141. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82):1-20.
142. Di Lorenzo G, Mansueto P, Pacor ML, et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009;123:1103-10, 10 e1-4.
143. Shamji MH, Wilcock LK, Wachholz PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006;317:71-9. (Pubitemid 44816327)
144. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010;40:598-606.
145. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985;76:734-44. (Pubitemid 16249375)
146. Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 2007;62:1023-8. (Pubitemid 47220978)
147. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients
148. Ebner C, Kraft D, Ebner H. Booster immunotherapy (BIT). Allergy 1994;49:38-42. (Pubitemid 24052789)
149. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306-12. (Pubitemid 34280657)
150. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006;61:198-201. (Pubitemid 43381830)
151. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997;100:293-300.
152. Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann Allergy Asthma Immunol 2007;98:416-26. (Pubitemid 46752634)
153. Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000;105(2 Pt 1):385-90. (Pubitemid 30109056)
154. Graft DF. Discontinuing venom immunotherapy. J Allergy Clin Immunol 1997;99:271. (Pubitemid 127743090)
155. Lerch E, Muller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-12.
156. van Halteren HK, van der Linden PW, Burgers JA, Bartelink AK. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997;100(6 Pt 1):767-70. (Pubitemid 28298994)
157. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991;88(3 Pt 1):339-48.
158. Golden DB. Discontinuation of venom immunotherapy. J Allergy Clin Immunol 1998;102(4 Pt 1):703-4.
159. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996;97:579-87. (Pubitemid 26062755)
160. Oehling A. Bacterial immunotherapy in bronchial asthma. J Investig Allergol Clin Immunol 1997;7:14-9. (Pubitemid 27145935)
161. Matricardi PM, Bjorksten B, Bonini S, et al. Microbial products in allergy prevention and therapy. Allergy 2003;58:461-71. (Pubitemid 36649304)
162. Wang JH, Kwon HJ, Jang YJ. Staphylococcus aureus increases cytokine and matrix metalloproteinase expression in nasal mucosae of patients with chronic rhinosinusitis and nasal polyps. Am J Rhinol Allergy 2010;24:422-7.
163. Bousquet J, Anto J, Auffray C, et al. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy. 2011 Jan 24. doi: 10.1111/j.1398-9995.2010.02534.x.
164. Prescott SL, Noakes P, Chow BW, et al. Presymptomatic differences in Toll-like receptor function in infants who have allergy. J Allergy Clin Immunol 2008;122:391-9.
165. Rodriguez-Perez N, Penagos M, Portnoy JM. New types of immunotherapy in children. Curr Allergy Asthma Rep 2008;8:484-92.
166. Prescott SL, Macaubas C, Smallacombe T, et al. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999;353:196-200. (Pubitemid 29088031)
167. Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax 2000;55(Suppl 1):S2-S10. (Pubitemid 30468238)
168. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-7.
169. Prescott SL. Allergy: when does it begin and where will it end? Allergy 2003;58:864-7. (Pubitemid 37046683)
170. Cohon A, Arruda LK, Martins MA, et al. Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy. J Allergy Clin Immunol 2007;120:210-3. (Pubitemid 46990503)
171. Arikan C, Bahceciler NN, Deniz G, et al. Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004;34:398-405. (Pubitemid 38373002)
172. Gerstmayr M, Ilk N, Schabussova I, et al. A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-Bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. J Immunol 2007;179:7270-5.
173. Nayak A, Tripathy I, Levitt D. Novel Amb a 1 CpG oligode- oxyribonucleotide conjugate ragweed vaccine administered to children. J Allergy Clin Immunol 2006;117:S159.
174. Casale TB, Kessler J, Romero FA. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:454-6. (Pubitemid 44595091)
175. Guimaraes Junqueir de Queiros M, Oliveira Silva DA, Alves R, et al. Mite-specific immunotherapy using allergen and/or bacterial extracts in atopic patients in Brazil. J Investig Allergol Clin Immunol 2008;18:84-92. (Pubitemid 351872300)
176. Villa E, Garelli V, Braido F, Melioli G, Canonica G. May we strengthen the human natural defenses with bacterial lysates? WAO Journal 2010;3:S17-S23.
177. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000;106:840-3.
178. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004;92:225-7. (Pubitemid 38233660)
179. Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007;99:82-6. (Pubitemid 47075956)
180. Rodriguez Perez N, Ambriz Moreno Mde J, Pizarro Esquivel U. [Non-fatal systemic reactions caused by immunotherapy and skin tests]. Rev Alerg Mex 2002;49:69-73.
181. Rodriguez Perez N, Ambriz Moreno Mde J. [Safety of immunotherapy and skin tests with allergens in children younger than five years]. Rev Alerg Mex 2006;53:47-51.
182. Larenas Linnemann D, Rodriguez Perez N, Becerril M. [Adverse reactions to skin tests and immunotherapy in the practice of Mexican allergologists]. Rev Alerg Mex 2008;55:62-70.
183. Filley W, Aston C, Coifman R, et al. Safety of Home Immunotherapy. J Allergy Clin Immunol 2008;121:abstracts.
184. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001;87(1 Suppl 1):47-55. (Pubitemid 32661330)
185. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4-12.
186. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;12:CD002893.
187. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006;97:141-8. (Pubitemid 44272577)
188. Di Bona D, Plaia A, Scafidi V, et al. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010;126:558-66.
189. Larenas-Linnemann DE. Sublingual immunotherapy: dosing in relation to clinical and immunological efficacy. Allergy Asthma Proc 2008;29:130-9.
190. Larenas-Linnemann D. Subcutaneous and sublingual immunotherapy in Children: complete update on controversies, dosing and efficacy. Curr Allergy Asthma Rep 2008;8:465-74.
191. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000;55:842-9. (Pubitemid 30643909)
192. Marogna M, Spadolini I, Massolo A, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005;115:1184-8. (Pubitemid 40824587)
193. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-7. (Pubitemid 39330257)
194. Marogna M, Spadolini I, Massolo A, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009;102:69-75.
195. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609. (Pubitemid 351367366)
196. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006;61:1162-72. (Pubitemid 44326350)
197. Larenas-Linnemann DE, Cox LS. Sublingual immunotherapy for asthma: need for high quality meta-analyses to prove the concept. Allergy 2007;62:704-5. (Pubitemid 46763430)
198. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immuno. 2007;120:164-70. (Pubitemid 46990495)
199. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005;116:1073-9. (Pubitemid 41571791)
200. Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007;156:674-81. (Pubitemid 46452365)
201. Cistero Bahima A, Sastre J, Enrique E, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Investig Allergol Clin Immunol 2004;14:17-25. (Pubitemid 38506427)
202. Severino MG, Cortellini G, Bonadonna P, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 2008;122:44-8.
203. Rodriguez-Santos O. Sublingual immunotherapy for Allergic rhinitis and asthma in children from two to five years of age with mite allergy. Rev Alergia Mex 2008;55:71-5.
204. Rienzo VD, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560-4. (Pubitemid 40769277)
205. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6 e3.
206. Larenas-Linnemann D. Sublingual immunotherapy in children: more optimism today. Pediatr Allergy Immunol 2009;20:399-400.
207. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005;95:254-8. (Pubitemid 41376795)
208. Agostinis F, Tellarini L, Canonica GW, et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 2005;60:133.
209. Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021-35. (Pubitemid 44308083)
210. Passalacqua G, Guerra L, Compalati E, Canonica GW. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf 2007;2:117-23. (Pubitemid 46805543)
211. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008;63:374. (Pubitemid 351224673)
212. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006;61:1235. (Pubitemid 44326363)
213. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62:567-8. (Pubitemid 46608356)
214. Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol 2009;124:378-9.
215. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963-4.
216. Casale TB, Canonica GW, Bousquet J, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009;124:665-70.
217. Brimnes J RC, Urioste S, Lund K. Shorter Dosing Intervals of Sublingual Immunotherapy Lead to More Efficacious Treatment in a Mouse Model of Rhinitis. J Allergy Clin Immunol 2008;121):s263.
218. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45. (Pubitemid 350225683)
219. Sander I, Fleischer C, Meurer U, et al. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy 2009;64:1486-92.
220. Valovirta E, Jacobsen L, Ljorring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:1177-83. (Pubitemid 44326352)
221. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71.
222. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72-80, e1-2.
223. Bordignon V, Parmiani S. Variation of the skin end-point in patients treated with sublingual specific immunotherapy. J Investig Allergol Clin Immunol 2003;13:170-6. (Pubitemid 37408720)
224. Di Rienzo V, Puccinelli P, Frati F, Parmiani S. Grass pollen specific sublingual/ swallow immunotherapy in children: open-controlled comparison among different treatment protocols. Allergol Immunopathol (Madr) 1999;27:145-51. (Pubitemid 29336878)
225. Guerra L, Compalati E, Rogkakou A, et al. Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. Allergol Immunopathol (Madr) 2006;34:82-3. (Pubitemid 43844848)
226. Rodriguez F, Boquete M, Ibanez MD, et al. Once daily sublingual immunotherapy without updosing - A new treatment schedule. Int Arch Allergy Immunol 2006;140:321-6. (Pubitemid 44114477)
227. Lombardi C, Incorvaia C, Braga M, et al. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy 2009;64:849-54.
228. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73 e7.
229. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007;62:958-61. (Pubitemid 47037855)
230. Tahamiler R, Canakcioglu S, Yilmaz S, Isildak H. Long-term immunotherapy for perennial allergic rhinitis: relationship of specific IgG levels to skin-prick test results and clinical symptoms and signs. Ear Nose Throat J 2008;87:E29.
231. Ozdemir C, Yazi D, Gocmen I, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007;18:508-15. (Pubitemid 47206743)
232. Caffarelli C, Cardinale F, Povesi C, et al. Optimal duration of SLIT. Int J Immunopathol Pharmacol 2009;22(4 Suppl):17-22.
233. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immuno. 2010;125:131-8 e1-7.
234. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101:206-11.
235. Yuta A, Ogihara H, Miyamoto Y, et al. [The enhanced clinical efficacy by treated years and the sustained efficacy after treatment of sublingual immunotherapy for Japanese cedar pollinosis]. Arerugi 2010;59:1552-61.
236. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10. (Pubitemid 36241378)
237. Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol 2007;142:70-8. (Pubitemid 46032987)
238. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969-75.
239. Cox L, Compalati E, Canonica W. Will sublingual immunotherapy become an approved treatment method in the United States? Curr Allergy Asthma Rep 2011;11:4-6.
240. Agostinis F, Foglia C, Landi M, et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 2008;63:1637-9.
241. Canonica GW, Passalacqua G. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. Allergy 2006;61(Suppl 81):20-3.
242. Ariano R, Berto P, Incorvaia C, et al. Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. Ann Allergy Asthma Immuno. 2009;103:254-9.
243. Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2006;96:600-5.
244. Simons FE, Simons KJ. Epinephrine (adrenaline) in anaphylaxis. Chem Immunol Allergy 2010;95:211-22.
245. Simons FE. Anaphylaxis: Recent advances in assessment and treatment. J Allergy Clin Immunol 2009;124:625-36; quiz 37-8.
246. Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions - guidelines for healthcare providers. Resuscitation 2008;77:157-69.
247. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy 2008;63:1061-70.
248. Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2009;64:204-12.
249. Rudders SA, Banerji A, Corel B, et al. Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics 2010;125:e711-8.
250. Westfall T, Westfall D. Adrenergic agonists and antagonists. In: Ed. t, editor. Goodman and Gillman's The Farmacological basis of therapeutics. 11th ed. New York: McGraw-Hill. 2006;pp:215-68.
251. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998;101(1 Pt 1):33-7. (Pubitemid 28112878)
252. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001;108:871-3. (Pubitemid 33096224)
253. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992;327:380-4.
254. Tole JW, Lieberman P. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. Immunol Allergy Clin North Am 2007;27:309-26. (Pubitemid 46686990)
255. Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol 2009;123:493-8.
256. Rawas-Qalaji M, Simons FE, Collins D, Simons KJ. Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxis. Ann Allergy Asthma Immunol 2009;102:500-3.
257. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-17.
258. Owen CG, Shah A, Henshaw K, et al. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004;54:451-6. (Pubitemid 38771894)
259. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007;62:830-7. (Pubitemid 47037864)
260. Winbery SL, Lieberman PL. Histamine and antihistamines in anaphylaxis. Clin Allergy Immunol 2002;17:287-317.
261. Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000;55:484-8. (Pubitemid 30230359)
262. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2000;15(S1):S3-S30.
263. Welch MJ, Meltzer EO, Simons FE. H1-antihistamines and the central nervous system. Clin Allergy Immunol 2002;17:337-88.
264. Hindmarch I, Johnson S, Meadows R, et al. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001;17:241-55. (Pubitemid 34150432)
265. Cobb DB, Watson WA, Fernandez MC. High-dose loratadine exposure in a six-year-old child. Vet Hum Toxicol 2001;43:163-4. (Pubitemid 32436287)
266. Simons FE. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol 1999;104(2 Pt 1):433-40. (Pubitemid 29420443)
267. Simons FE. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol 2007;18:535-42. (Pubitemid 47206747)
268. Schatz M. H1-antihistamines in pregnancy and lactation. Clin Allergy Immunol 2002;17:421-36.
269. Di Rosa M, Flower RJ, Hirata F, Parente L, Russo-Marie F. Anti-phospholipase proteins. Prostaglandins 1984;28:441-2.
270. Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990;141(2 Pt 2):S59-69. (Pubitemid 20063272)
271. Schleimer RP, Schulman ES, MacGlashan DW Jr, et al. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest 1983;71:1830-5. (Pubitemid 13056786)
272. Daeron M, Sterk AR, Hirata F, Ishizaka T. Biochemical analysis of glucocorticoid- induced inhibition of IgE-mediated histamine release from mouse mast cells. J Immunol 1982;129:1212-8. (Pubitemid 12055596)
273. Greaves MW, Plummer VM. Glucocorticoid inhibition of antigen-evoked histamine release from human skin. Immunology 1974;27:359-64.
274. Clark S, Bock SA, Gaeta TJ, et al. Multicenter study of emergency department visits for food allergies. J Allergy Clin Immunol 2004;113:347-52. (Pubitemid 38210561)
275. Clark S, Long AA, Gaeta TJ, Camargo CA, Jr. Multicenter study of emergency department visits for insect sting allergies. J Allergy Clin Immunol 2005;116:643-9. (Pubitemid 41267141)
276. Gaeta TJ, Clark S, Pelletier AJ, Camargo CA. National study of US emergency department visits for acute allergic reactions, 1993 to 2004. Ann Allergy Asthma Immunol 2007;98:360-5. (Pubitemid 46582128)
277. Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2010;65:1205-11.